Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glaxo/SB Supply Chain Alignment Will Ease Second Merger Attempt - Garnier

Executive Summary

The second attempt at a merger of SmithKline Beecham and Glaxo Wellcome is more likely to succeed because the companies have aligned their manufacturing operations in the two years since the first engagement, CEO-designate Jean-Pierre Garnier, PhD, told the House of Commons Science & Technology Select Committee Feb. 22 in London.

You may also be interested in...



GSK Manufacturing Consolidation Has Helped GMP Compliance, Firm Says

GlaxoSmithKline's manufacturing streamlining has helped the company avoid trouble during the recent round of FDA good manufacturing practices enforcement, CEO J.P. Garnier told investors Oct. 23

GSK Manufacturing Consolidation Has Helped GMP Compliance, Firm Says

GlaxoSmithKline's manufacturing streamlining has helped the company avoid trouble during the recent round of FDA good manufacturing practices enforcement, CEO J.P. Garnier told investors Oct. 23

Seroquel, Atacand Lead AstraZeneca New Products; Prilosec Nears $6 Bil.

The anti-psychotic Seroquel is one of the fastest growing products in the AstraZeneca portfolio, with sales totaling $232 mil. in 1999, the company indicated at its 1999 operating results review Feb. 24 in London.

Related Content

UsernamePublicRestriction

Register

LL1133990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel